“…Deficits in the GABAergic system are associated with various motor and cognitive disorders such as Huntington disease (Pinborg et al, 2001), primary dystonia (Garibotto et al, 2011), ischemic stroke (Heiss et al, 2004), vascular parkinsonism (Ihara et al, 2007), epilepsy (Galanopoulou, 2010), schizophrenia (Lewis et al, 2005), autism (Fatemi et al, 2009) and major depressive disorder (Luscher and Shen, 2011;Luscher et al, 2011a). However, pharmacological therapies to extrinsically enhance or reduce the GABAergic system are not always sufficient in ameliorating symptoms (Doggett, 2004;Kalia et al, 2013;Frank, 2014;Pilleri and Antonini, 2015;Walker et al, 2015).…”